NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2012

Primary Completion Date

October 31, 2018

Study Completion Date

April 30, 2019

Conditions

Aggressive Non-Hodgkin LymphomaBlasts Under 5 Percent of Bone Marrow Nucleated CellsChronic Lymphocytic LeukemiaLoss of Chromosome 17pMyelodysplastic/Myeloproliferative NeoplasmNon-Hodgkin LymphomaProlymphocytic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Aggressive Adult Non-Hodgkin LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Plasma Cell MyelomaRecurrent Small Lymphocytic LymphomaWaldenstrom Macroglobulinemia

Interventions

DRUG

Atorvastatin Calcium

Given PO

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mycophenolate Mofetil

Given PO or IV

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo nonmyeloablative allogeneic PBSC transplant

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo nonmyeloablative allogeneic PBSC transplant

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (2)

80218

Presbyterian - Saint Lukes Medical Center - Health One, Denver

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER